Lung Cancer

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

Case Reports, Lung Cancer

Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer

Carrie L. Barnhart, PharmD, BCOP, and David F. Christianson, MD

Lung Cancer

2022 Midyear Review: Non–Small-Cell Lung Cancer

Meeting Highlights Online Only

AACR Highlights, Lung Cancer

First-Line Sotorasib Shows Long-Lasting Responses in Metastatic NSCLC with KRAS Mutation

FDA Oncology Update, Lung Cancer, Checkpoint Inhibitors

Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC

Lung Cancer

NSCLC Year in Review Introduction

Lung Cancer

The Impact of Symptom Severity on Multidisciplinary Tumor Board Treatment Decisions

Lung Cancer

Targeted Therapy and Immunotherapy May Improve NSCLC Survival Rates

Lung Cancer

CodeBreaK 100 Phase 2 Study Results Demonstrate Sotorasib Efficacy

Lung Cancer

FDA Grants Accelerated Approval of Sotorasib for Patients with NSCLC Harboring KRAS Mutations

Lung Cancer

Role of Exercise and Energy Conservation in the Management of Fatigue in Patients with NSCLC Receiving Immune-Oncology Therapy

Page 1 of 12
Results 1 - 10 of 114